Our search terms were “NLRP3 inflammasome, multiple sclerosis, experimental autoimmune encephalomyelitis, natural compound, autophagy, small molecular compound, inflammation, mechanism, therapy”. We ...

The NLRP3 inflammasome is implicated in a host ... in preclinical development but being eyed as a possible treatment for multiple sclerosis. Brian Hilberdink, Boehringer Ingelheim's new Head ...

which has just reported phase 1 results with its first two NLRP3 inhibitors, and ZyVersa Therapeutics with preclinical-stage candidate IC 100 that is being considered for multiple sclerosis.

A new study suggests that high doses of vitamin D supplements could help reduce disease activity among multiple sclerosis ...

Treatment with tolebrutinib led to greater confirmed disability improvement at 6 months compared with placebo in patients ...

No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Previous research has shown that vitamin D deficiency can increase the risk of multiple sclerosis (MS) — and a new study suggests that supplementing it in high doses could help reduce symptoms.

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

A small molecule that blocks TYK2 in the brain showed promise for reducing disease activity in mouse models of multiple ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...